Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: GlobeNewswire
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company’s pipeline of small molecule programs with a focus on preparation for the commercial launch of azetukalner. “Matt joins Xenon at an exciting time of growth where his extensive operational, pharmaceutical development and manufacturing expertise will help support the advancement of our Phase 3 epilepsy and MDD programs, planning for
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]Canadian Business Journal
- Xenon to Report Q3 2024 Financial Results on November 12, 2024GlobeNewswire
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.MarketBeat
- Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual ConferenceGlobeNewswire
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.MarketBeat
XENE
Earnings
- 8/8/24 - Miss
XENE
Sec Filings
- 8/9/24 - Form S-3ASR
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- XENE's page on the SEC website